These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 7871913)
1. [Mild, moderate and severe dysplasia in exfoliative cytological studies of breast secretions in connection with use of oral contraceptives]. Wunderlich M Zentralbl Gynakol; 1994; 116(11):622-7. PubMed ID: 7871913 [TBL] [Abstract][Full Text] [Related]
2. [Breast diseases (fibroadenomas, mastopathies, breast cancers) in hormonal contraception]. Nizze H; Kändler U Zentralbl Gynakol; 1988; 110(20):1296-302. PubMed ID: 3239299 [TBL] [Abstract][Full Text] [Related]
3. Oral contraceptive use and fibrocystic breast disease among pre- and postmenopausal women. Berkowitz GS; Kelsey JL; LiVolsi VA; Holford TR; Merino MJ; Ort S; O'Connor TZ; Goldenberg IS; White C Am J Epidemiol; 1984 Jul; 120(1):87-96. PubMed ID: 6741927 [TBL] [Abstract][Full Text] [Related]
4. Oral contraceptive use and fibrocystic breast disease with special reference to its histopathology. Pastides H; Kelsey JL; LiVolsi VA; Holford TR; Fischer DB; Goldenberg IS J Natl Cancer Inst; 1983 Jul; 71(1):5-9. PubMed ID: 6575209 [TBL] [Abstract][Full Text] [Related]
5. Oral contraception and breast pathology. Ragni N; Boccardo E; Viglino S; Larosa E Acta Eur Fertil; 1981 Jun; 12(2):141-63. PubMed ID: 6794288 [TBL] [Abstract][Full Text] [Related]
12. [Contraception. Recommendations from a group of experts]. Lakartidningen; 1993 Oct; 90(40):3456-64. PubMed ID: 7901465 [TBL] [Abstract][Full Text] [Related]
13. [Risk of breast cancer and oral contraceptives]. Thür L Z Lymphol; 1991 Jun; 15(1):1-12. PubMed ID: 1927006 [TBL] [Abstract][Full Text] [Related]
14. Cystic disease, family history of breast cancer, and use of oral contraceptives. Vakil DV; Elinson L; Morgan RW Cancer Detect Prev; 1981; 4(1-4):511-5. PubMed ID: 7349817 [TBL] [Abstract][Full Text] [Related]
17. The risk of serious illness among oral contraceptive users: evidence from the RCGP's oral contraceptive study. Hannaford PC; Kay CR Br J Gen Pract; 1998 Oct; 48(435):1657-62. PubMed ID: 10071398 [TBL] [Abstract][Full Text] [Related]
18. Safety implications of transferring the oral contraceptive from prescription-only to over-the-counter status. Potts M; Denny C Drug Saf; 1995 Dec; 13(6):333-7. PubMed ID: 8652077 [TBL] [Abstract][Full Text] [Related]
19. Oral contraceptive use and fibrocystic breast disease of different histologic classifications. Hsieh CC; Crosson AW; Walker AM; Trapido EJ; MacMahon B J Natl Cancer Inst; 1984 Feb; 72(2):285-90. PubMed ID: 6582316 [TBL] [Abstract][Full Text] [Related]